Dry eye common in early GO

Article

According to recent data, dry eye has been found to be common in patients with early Graves Ophthalmology (GO).

According to recent data, dry eye has been found to be common in patients with early Graves Ophthalmology (GO).

Dr Vasilis Achtsidis et al., Attikon University Hospital, University of Athens, Greece, evaluated a total of 52 eyes of 26 patients with early GO and 37 control subjects. GO diagnosis was based on the European Group on Graves Orbitopathy consensus statement. The team also calculated Clinical Activity Score (CAS) and Werner-NOSPECS Score, as well as corneal sensitivity using a Cochet-Bonnet aesthesiometer.

Of the participants included in the study, 67.8% with early GO and 13.5% of healthy controls presented with ocular surface dryness. Mean Schirmer test scores were significantly lower in GO patients, compared to controls and these results correlated with CAS. Tear film break up time was lower in patients by 5.46 seconds and 5.74 seconds in the right and left eyes, respectively.

Dry eye is common in GO, despite the absence of apparent exophthalmos, and based on the results the team concluded that there was an association with CAS as well as reduced corneal sensitivity.

To read the abstract please visit the European Journal of Ophthalmology.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.